Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doxorubicin prodrug SLNP-IC1
- Development stage
- Approved
- Lead developer
- Nammi Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
SLNP-IC1 is a novel solid lipid nanoparticle (SLNP) formulation of a doxorubicin prodrug (referred to as IC1), developed by Nammi Therapeutics. This drug is designed to improve the therapeutic window of doxorubicin by enhancing its stability, efficacy, and safety in preclinical studies. The SLNP formulation significantly reduces the release of free doxorubicin in human serum compared to liposomal formulations like Doxil, leading to improved tumor growth inhibition and reduced toxicity at higher doses in animal models. The mechanism of action relies on the cytotoxic effects of doxorubicin delivered via a nanoparticle carrier system for targeted cancer therapy[1].
- Other names
- IC1 prodrugIC-1 prodrugIC 1 prodrugNammisome-formulated doxorubicin prodrug
02
Targets
TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on Doxorubicin prodrug SLNP-IC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Doxorubicin prodrug SLNP-IC1.